- Product Details
Keywords
- 152121-47-6 manufacturer
- SB203580 manufacturer
- RWJ 64809, PB 203580
Quick Details
- ProName: SB203580
- CasNo: 152121-47-6
- Molecular Formula: C21H16FN3OS
- Appearance: yellow solid
- Application: for research
- DeliveryTime: 1 week
- PackAge: foil bag
- Port: shanghai\Tianjin
- ProductionCapacity: 10 Kilogram/Week
- Purity: 99%
- Storage: Keep away from fire and heat source;ke...
- Transportation: EMS\DHL\FEDEX\TNT...
- LimitNum: 1 Gram
- Mol weight: 377.43
Superiority
· Synonyms: SB-203580, RWJ 64809, PB 203580
· Target 1: p38 MAPK
· Purity: >98%
· Solubility: Soluble in DMSO (50 mg/mL), and slightly soluble in water.
· Storage: Store at -20 oC for the stability of two years.
· Stock: Yes
SB203580 inhibits the IL-2-induced proliferation of primary human T cells, murine CT6 T cells, or BAF F7 B cells with an IC50 of 3–5 μm. SB203580 also inhibits IL-2-induced p70S6 kinase activation, although the concentration required is slightly higher with an IC50 above 10 μm. SB203580 also inhibits the activity of PDK1 in a dose-dependent manner with an IC50 in the 3–10 μm range. SB203580 inhibits p38-MAPK stimulation of MAPKAPK2 with an IC50 of approximately 0.07 μM, whereas inhibits total SAPK/JNK activity with an IC50 of 3–10 μM. SB203580 at higher concentrations activates the ERK pathway, which subsequently enhances NF-κB transcriptional activity. SB203580 induces autophagy in human hepatocellular carcinoma (HCC) cells.
Details
· Synonyms: SB-203580, RWJ 64809, PB 203580
· Target 1: p38 MAPK
· Purity: >98%
· Solubility: Soluble in DMSO (50 mg/mL), and slightly soluble in water.
· Storage: Store at -20 oC for the stability of two years.
· Stock: Yes
SB203580 inhibits the IL-2-induced proliferation of primary human T cells, murine CT6 T cells, or BAF F7 B cells with an IC50 of 3–5 μm. SB203580 also inhibits IL-2-induced p70S6 kinase activation, although the concentration required is slightly higher with an IC50 above 10 μm. SB203580 also inhibits the activity of PDK1 in a dose-dependent manner with an IC50 in the 3–10 μm range. SB203580 inhibits p38-MAPK stimulation of MAPKAPK2 with an IC50 of approximately 0.07 μM, whereas inhibits total SAPK/JNK activity with an IC50 of 3–10 μM. SB203580 at higher concentrations activates the ERK pathway, which subsequently enhances NF-κB transcriptional activity. SB203580 induces autophagy in human hepatocellular carcinoma (HCC) cells.
references:
[1] Cuenda A. et al., SB 203580 is a specific inhibitor of a MAP kinase Homologue which is stimulated by cellular stresses and interleukin-1. FEBS Lett. 364:229-233(1995).
[2] Lali FV.et al.,The pyridinyl imidazole inhibitor SB203580 blocks phosphoinositide-dependent protein kinase activity, protein kinase B phosphorylation, and retinoblastoma hyperphosphorylation in interleukin-2-stimulated T cells independently of p38 mitogen-activated protein kinase. J Biol Chem. 275(10):7395-402 (2000).
[3] Jarnicki AG.et al., Attenuating Regulatory T Cell Induction by TLR Agonists through Inhibition of p38 MAPK Signaling in Dendritic Cells Enhances Their Efficacy as Vaccine Adjuvants and Cancer Immunotherapeutics. J. Immunol., 180: 3797-3806 (2008).
[4] Borsch-Haubold et al., Direct inhibition of cyclooxygenase-1 and -2 by the kinase inhibitors SB 203580 and PD 98059. J.Biol.Chem.273:28766 (1998).